KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Operating Leases (2019 - 2026)

Palvella Therapeutics has reported Operating Leases over the past 4 years, most recently at $12.2 million for Q4 2022.

  • Quarterly Operating Leases fell 11.54% to $12.2 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $12.2 million through Dec 2022, down 11.54% year-over-year, with the annual reading at $12.2 million for FY2022, 11.54% down from the prior year.
  • Operating Leases was $12.2 million for Q4 2022 at Palvella Therapeutics, up from $11.4 million in the prior quarter.
  • Over five years, Operating Leases peaked at $15.9 million in Q4 2020 and troughed at $11.4 million in Q3 2022.
  • The 4-year median for Operating Leases is $14.9 million (2020), against an average of $14.3 million.
  • Year-over-year, Operating Leases grew 6.09% in 2021 and then fell 22.52% in 2022.
  • A 4-year view of Operating Leases shows it stood at $15.5 million in 2019, then increased by 2.89% to $15.9 million in 2020, then decreased by 13.12% to $13.8 million in 2021, then fell by 11.54% to $12.2 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Operating Leases are $12.2 million (Q4 2022), $11.4 million (Q3 2022), and $12.3 million (Q2 2022).